Menu

Wound-Healing in Mice Triggers Growth of Dormant Tumors

Treating mice with anti-inflammatory drugs following surgery reduced the size of tumors.

Apr 12, 2018
Jim Daley

ISTOCK, SIDSNAPPER

The wound-healing process after cancer surgery can cause dormant tumors to begin growing in injured mice, researchers reported yesterday (April 11) in Science Translational Medicine. The finding may explain why metastatic recurrence is common in breast cancer patients following surgery.

“It’s not the actual surgery, but instead, it’s the post-surgical wound response,” coauthor Robert Weinberg, a biologist at MIT, tells USA Today. “It is provoking already disseminated cells to begin to grow into clinically detectable metastases.”

Weinberg and his colleagues observed that T cells prevented tumors from proliferating by keeping them in a dormant state. They hypothesized that when the immune system is preoccupied with wound recovery, its ability to keep cancer cells in check is compromised. To test whether cancer surgery could cause the cancer cells to awaken, they first injected mice with breast cancer cells, allowed tumors to grow, and then surgically removed previously implanted sterile sponges from the mice. The sponges were used to model the resection of a mass, while the tumors were left intact to avoid disturbing them and to maintain consistency across the animals.

They found that in mice who were operated on, 60 percent of the tumors continued to grow. In control mice that did not undergo surgery, only 10 percent of tumors persisted.

A previously published study found that anti-inflammatory analgesics reduced the rates of metastatic relapse in breast cancer patients. Based on this, the researchers treated mice with meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), to determine whether it would impact their tumor growth. Cancers were much smaller in wounded mice who were treated with meloxicam than mice who were given saline controls. The treatment did not affect tumor growth in non-wounded mice.   

“I do not know if this mimics the potential effect of a lumpectomy or mastectomy, but the inflammatory response to an implanted foreign body would be expected to be quite robust,” Deanna Attai, a breast surgeon at the University of California, Los Angeles, tells STAT. It may be the inflammation causing the dormant cancer cells to activate, rather than anything associated with surgery, she adds.

See “Tumor Traps

 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.